Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019041 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT04019041 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 153 participants.
The verdict
NCT04019041, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly injections of placebo.
Interventions
- DRUG placebo
- DRUG bermekimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2020-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019041
The ClinicalTrials.gov registry entry for NCT04019041 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04019041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04019041 about?
NCT04019041 is a clinical study titled "A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa". This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly inje...
What is the current status of trial NCT04019041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2019-09-16. Estimated completion is 2020-11-17.
What interventions are being tested in trial NCT04019041?
The interventions under investigation include: placebo (DRUG), bermekimab (DRUG).
Who is sponsoring clinical trial NCT04019041?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.